Condition: Preterm Birth · Sponsor: Rutgers, The State University of New Jersey
The goal of this randomized clinical trial is to assess sulfasalazine as a potential treatment to prevent recurrent preterm birth. The main questions it aims to answer are: * Does sulfasalazine down regulate corticotropin releasing hormone (CRH) levels in pregnant persons with a prior history of preterm birth? * Does sulfasalazine reduce the incidence of recurrent preterm birth in pregnant persons given drug vs. controls? Consenting participants will be randomized to receive sulfasalazine or to a control group and will undergo serial blood draws to assess plasma CRH levels.
This description comes directly from the study's public registry record.
Vanessa Martinez, MPH · 2017379179 · vm310@rwjms.rutgers.edu
Emily Rosenfeld, DO · 7324024960 · er720@rwjms.rutgers.edu
Always discuss trial participation with your own doctor first.
| Rutgers Robert Wood Johnson Medical School | New Brunswick, New Jersey, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05703425